Short-Term Results After Single-Dose Intravitreal Bevacizumab Treatment for Macular Edema Secondary to Central and Branch Retinal Vein Occlusions

Abstract

INTRODUCTION[|]The aim of the present study was to investigate changes in short-term visual acuity and foveal thickness after single-dose intravitreal bevacizumab treatments for macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).[¤]METHODS[|]The patients were separated into 2 groups: 18 eyes of 18 patients with BRVO, and 10 eyes of 10 patients with CRVO. Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity scores, changes in foveal thickness measured with optical coherence tomography, and complications of treatment were evaluated.[¤]RESULTS[|]In each monthly measurement, in the BRVO group, foveal thickness decreased from baseline statistically significantly from baseline (p<0.05) and ETDRS score of visual acuity increase also was statistically significant (p<0.05) at each interval. In the CVRO group, although 1 month after injection, foveal thickness decreased significantly (p<0.05), and second and third months, the reduction in foveal thickness was not statistically significant (p>0.05) and compared with preinjection values, increase ETDRS score at all months was not statistically significant (p>0.05).[¤]DISCUSSION AND CONCLUSION[|]Treatment of macular edema secondary to BRVO with intravitreal injection of bevacizumab in the early stages was effective and reliable.[¤]

Keywords

• macular edema
• retinal vein occlusion; single-dose intravitreal bevacizumab.